Dr. Amit Kumar, Ph.D
Dr. Amit Kumar, Ph.D Executive Chairman

Dr. Kumar, the inventor of our Cchek™ technology, has been an investor, founder, director and CEO of several technology enterprises, both public and private. As CEO, he took CombiMatrix Corporation public and ran it for a decade while listed on the NASDAQ Global Market. He has worked in venture capital with OAK Investment Partners, and has been an advisor to investment funds, venture capital firms, and Fortune 500 companies. He was on the Board of Directors of Acacia Research Corporation from 2002-2008. Dr. Kumar is currently Vice-Chairman of ITUS Corporation, Executive Chairman of ITUS' wholly-owned subsidiary Anixa Diagnostics, and he sits on the Board of other public and private companies. He received his AB in Chemistry from Occidental College. After graduate studies at Stanford University and Caltech, he received his Ph.D. from Caltech and followed that with a post-doctoral fellowship at Harvard.

Robert Berman
Robert Berman President and Chief Executive Officer, Director

Mr. Berman has experience in a broad variety of areas including finance, acquisitions, marketing, and the development and licensing of emerging technologies. From 2000 to 2008, Mr. Berman was the Chief Operating Officer and General Counsel of Acacia Research Corporation, a publicly traded technology development company focused on intellectual property. Mr. Berman has written several articles and has made television and radio appearances discussing the status of cancer diagnostics including FOX News, Forbes, and OncaZine, and has lectured at preeminent educational institutions such as Harvard Law School, UCLA's Anderson School of Business, and USC's Marshall School of Business. Mr. Berman received a B.S. from the University of Pennsylvania's Wharton School, and a J.D. from Northwestern Law School, where he is an adjunct faculty member.

Dr. Arnold Baskies, Ph.D
Dr. Arnold Baskies, Ph.D Director

Dr. Baskies, Chairman of the National Board of Directors of the American Cancer Society, is a board certified general surgeon and fellowship trained surgical oncologist with special interests in breast cancer, thyroid cancer, and melanoma. Dr. Baskies currently has been a member of  Virtua Surgical Specialists, a multi-specialty practice since 2011. In addition to his pioneering efforts to promote the latest surgical and nonsurgical techniques, including minimally invasive surgery (and advanced radioguided techniques) for diseases of the breast, thyroid, and parathyroid glands, he has cared for thousands of surgical patients in his 30-year career. Dr. Baskies received his Bachelor of Arts degree summa cum laude and was a member of Phi Beta Kappa at Boston University, graduated from the Boston University School of Medicine, completed his surgical residency at Boston Medical Center, and had fellowship training in surgical oncology at the National Cancer Institute.

Dr. John Monahan, Ph.D
Dr. John Monahan, Ph.D Director

Dr. Monahan is an experienced CEO-level executive and has served on a number of biotechnology company boards over the years. He is currently a Scientific Advisory Consultant for Synthetic Biologics, Inc. (NYSE MKT: SYN) and from 2010 through 2015 he was the Sr. Executive Vice President of Research & Development Synthetic Biologics, Inc. He is also a director of Heat Biologics, Inc. (Nasdaq: HTBX), a position that he has held since 2011, and was a director of Tacere Therapeutics, Inc., a wholly-owned subsidiary of Benitec Biopharma Limited (Nasdaq: BNTC) from 2006 to 2015. In addition to his work with public companies, Dr. Monahan is also currently a member of the Scientific Advisory Board of Agilis Biotherapeutics, Inc., a position that he has held since 2014, and is a board member of several other biotechnology companies. In addition, in 1992 he founded Avigen, Inc., a biotech company that pioneered the development of gene medicines based on adeno-associated virus vectors, now an industry standard. Over a 12-year period as its CEO, Dr. Monahan took Avigen public through an initial public offering raising over $235M and led the company through several Investigational New Drug (IND) applications. Prior to Avigen, Dr. Monahan served as Vice President - Research and Development at Somatix B.V., and Director of Molecular & Cell Biology at Triton Biosciences, Inc. He was also previously Research Group Chief, Department of Molecular Genetics at Hoffmann-LaRoche Inc., and Adjunct Assistant Professor, Department of Cell Biology at New York University. Dr. Monahan earned a Ph.D. in Biochemistry from McMaster University, Hamilton, Canada, and a B.S. in Science from University College, Dublin, Ireland. Dr. Monahan has over 50 publications in scientific literature and has made hundreds of presentations in public TV appearances, to scientific groups, investors and the general public over the years.

Dale Fox
Dale Fox Director

Mr. Fox is an accomplished entrepreneur and innovator who has successfully launched five companies and brought over 25 hardware and software products to market. He is currently the CEO of Tribogenics, a start-up company he co-founded in 2011 that develops portable, powerful X-ray devices based upon a new technology conceived and licensed from the University of California, Los Angeles. Mr. Fox has raised numerous rounds of capital for many types of companies, including venture capital, strategic investments, and other financings. A master at networking, Mr. Fox has built world-class executive and advisory teams. He received a Bachelor of Business Administration degree from Southern Methodist University's Cox School of Business with advanced studies at the Wharton program in Copenhagen. Mr. Fox continues to mentor young entrepreneurs and has taught classes on the subject at the Founders Institute, the University of Southern California and Loyola Marymount University.